Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
SWOG S2206: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Thistrial is available at multiple Sutter locations. Please contact one of thefollowing the study:
Site Point of Contacts:
Alta Bates (CA164)
Painte’ Berniard Piante.Berniard@sutterhealth.org
California Pacific Medical Center (CA222)
Sophia Vu (Manager) Sophia.Vue@sutterhealth.org
Eden Medical Center (CA200)
Leah Galvez Leah.Galvez@sutterhealth.org
Mills Health Center (CA209)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
Memorial Medical Center (CA182)
Kristen Moorman Kristen.Moorman@sutterhealth.org
Palo Alto Medical Foundation (PAMF – All sites)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
SIMR Sutter Institute for Medical Research (SIMR – All sites)
Kirsten Babski Kirsten.Babski@sutterhealth.org
Sutter Cancer Research Consortium
NCIClinicalTrials@sutterhealth.org
Principal Investigator
Related Studies
Impact of COVID-19 on Cancer Care Management
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS
Dana Farber 13-09-259 DCIS Registry
Investigator: Kristie A. Bobolis, M.D.